Catalog Products » Complement C1s, His, Human
Manual
Manual
COAs

Complement C1s, His, Human

Complement C1s protease inhibitors have potential utility in the treatment of diseases associated with activation of the classical complement pathway such as humorally mediated graft rejection, ischemia-reperfusion injury (IRI), vascular leak syndrome, and acute respiratory distress syndrome (ARDS).
$390.00
Z05189-100

Ask us a question
Product Introduction
Species Human
Protein Construction
Complement C1s (Glu16-Asp688)
Accession # P09871		 His
N-term C-term
Purity > 90% as determined by Bis­-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 75.98 kDa
Apparent Molecular Weight Due to enzyme lysis glycosylation, the protein migrates to 55-60 kDa (light chain), 32-35 kDa (heavy chain) and 76-96 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Dissolve the lyophilized protein in distilled water. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1mg/ml for 500μg or 1mg lyophilized powder. Do not mix by vortex or vigorous shaking.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

Complement C1s, His, Human

Immobilized Complement C1s, His, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-C1S Antibody, hFc Tag with the EC50 of 9.6ng/ml determined by ELISA. »

Complement C1s, His, Human

Complement C1s, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 90%. »

<
>

Background
Target Background Complement C1s protease inhibitors have potential utility in the treatment of diseases associated with activation of the classical complement pathway such as humorally mediated graft rejection, ischemia-reperfusion injury (IRI), vascular leak syndrome, and acute respiratory distress syndrome (ARDS).
Synonyms EDSPD2; C1 esterase;Complement Component C1s
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.